Alan P. Kozikowski, Ph.D. Alan Kozikowski

Department of Medicinal Chemistry and Pharmacognosy

University of Illinois at Chicago
College of Pharmacy
833 S. Wood Street (M/C 781)
Chicago, IL 60612-7231

Office: 531A PHARM
Office Phone:
(312) 996-7577
Fax Number: (312) 996-7107
email address:


Ph.D. (Organic Chemistry) 1974, University of California, Berkeley

Course Materials:

MDCH 561:

Positions Available:

Postdoctoral positions are available in synthetic organic/medicinal chemistry. Potential applicants must have a Ph.D. degree in chemistry and be skilled in the art of organic synthesis. Interested applicants should forward their curriculum vitae plus three letters of recommendation to Dr. Alan Kozikowski.

Research Interests:

Dr. Kozikowski's group is a medicinal chemistry group that is involved in research at the interface of organic chemistry and biology. Specifically, the the group uses the latest methods of organic synthesis combined with information gleaned from the methods of molecular modeling (both small molecule and protein modeling) to design and synthesize molecules that can be used to gain a better understanding of the function of specific molecular targets. A host of new target macromolecules continue to be identified as a consequence of the power of molecular biology, combined with a better understanding of signal transduction pathways and gene transcription. The research has generated several novel pharmacological research tools which may serve as a steppingstone to the design of therapeutic agents. The modeling methods involve extensive computational experience, whereas the preparation of a specific target molecule in the lab utilizes techniques of organic chemistry coupled with modern methods of chemical analysis including FT-IR, high field NMR, GC-MS. Additionally, the chemistry group makes use of combinatorial chemistry methods and has one of the latest robotics systems for chemical library generation.

Dr. Kozikowski's group focuses on broad areas of neuroscience. The group was the first in the world to carry out the synthesis of the Alzheimer's agent huperzine A. In collaboration with researchers at WRAIR, this remarkable molecule has been shown to work as a potent of acetylcholinesterase and to possess neuroprotective properties through its action at NMDA receptors. Because of much of Dr. Kozikowski's efforts, this molecule is now currently marketed for use in the treatment of memory disorders. The group is also actively involved in the generation of novel transporter ligands, and in particular, in the identification of therapeutics for the treatment of cocaine abuse. Presently, the group has identified a transporter ligand that acts only partially like cocaine. This molecule has been studied in primates, and is being further advanced by NIDA's medications development program for use in humans. The group is also actively involved in the identification of new tools for furthering our understanding of a family of glutamate receptors know as the metabotropic glutamate family, in collaboration with Dr. Joe Neale and Jarda Wroblewski. Again, novel ligands have been found which have been shown to act in unique ways, and which possess neuroprotective properties. Lastly, the group has been active in the design of agents that act at the regulatory site of PKC. These efforts involve extensive molecular modeling of the target protein. As PKC is a ubiquitous signaling molecule, ligands capable of binding to it have potential use in Alzheimer's disease. Through the collaborative projects with neuroscientists at GUMC, ligands developed for binding to PKC have been found effective in the modulation of amyloid processing.

Other research-related information and files:

"Creating National Medicinal Chemistry Resource Centers" - [PDF] presentation from Doctors Without Borders, No Time To Wait: Overcoming Gaps in TB Drug Research and Development, 2007 Symposium, New York City.